BIBLIOGRAPHIC RECORD

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.

This record contains bibliographic metadata. Open the linked source to check the work; the record does not include its full text.

Recorded authors
John Marsden; Mike Kelleher; Eilish Gilvarry; Luke Mitcheson; Jatinder Bisla; Angela Cape; Fiona Cowden; Edward Day; Jonathan Dewhurst; Rachel Evans; Will Hardy; Andrea Hearn; Joanna Kelly; Natalie Lowry; Martin McCusker; Caroline Murphy; Robert Murray; Tracey Myton; Sophie Quarshie; Rob Vanderwaal; April Wareham; Dyfrig Hughes; Zoë Hoare
Source of metadata
PubMed
Year recorded
2023

Public identifiers and source

Open the source record

Reference

John Marsden; Mike Kelleher; Eilish Gilvarry; Luke Mitcheson; Jatinder Bisla; Angela Cape; Fiona Cowden; Edward Day; Jonathan Dewhurst; Rachel Evans; Will Hardy; Andrea Hearn; Joanna Kelly; Natalie Lowry; Martin McCusker; Caroline Murphy; Robert Murray; Tracey Myton; Sophie Quarshie; Rob Vanderwaal; April Wareham; Dyfrig Hughes; Zoë Hoare. (2023). Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/38045803/

Reference assembled from the available metadata. Check and cite the original publication before reusing a claim.

Permanent record URL: https://brain.psiconautica.org/en/documentos/d-e2804a6524e0d4c99605165d53e58eeb/